The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
March Biosciences Closes $28.4 Million Series A Financing for Advancing MB-105 Therapy
Oct 23, 2024•over 1 year ago
Contract Type
partnership
HoustonBiotechnology
Description
March Biosciences has closed an oversubscribed $28.4 million Series A financing led by Mission BioCapital and 4BIO Capital, raising over $51 million to date. The funds will support the Phase 2 development of March Bio’s lead CD5 CAR-T therapy, MB-105, for T-cell lymphoma and pipeline candidates.
Company Information
Company
March Biosciences
Location
7255 Helix Park
Houston, Texas, United States
About
March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company's pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.
HoustonBiotechnology